Engimmune Therapeutics Raises CHF 15.5M in Seed Financing
Summary
The round was led by Pureos Bioventures and Novo Holdings with incubation from BaseLaunch. By applying proprietary platform technologies combining genome editing, functional high-throughput screening, deep sequencing and machine learning, Engimmune addresses key efficacy and safety challenges that currently limit the full potential of TCR-T cell and soluble TCR therapeutics. Its lead products are focused on oncology, with potential to expand to autoimmune diseases in the future. Engimmune Therapeutics also announced the appointment of TCR pioneer and industry veteran Dr Bent Jakobsen as Chairman of the Board. Former chief scientist and co-founder of Immunocore, a soluble TCR therapeutics company, and Adaptimmune, an adoptive TCR-T cell therapy company, Dr Jakobsen is a global expert in the field of T cell immunology.
Funding
Review available funding amount, funding date, investors, and linked company information related to Engimmune Therapeutics Raises CHF 15.5M in Seed Financing in the interactive ISVWorld profile.